{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:47:07Z","timestamp":1785008827193,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["16K09851"],"award-info":[{"award-number":["16K09851"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10637-019-00862-9","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T01:22:02Z","timestamp":1571966522000},"page":"1012-1019","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells"],"prefix":"10.1007","volume":"38","author":[{"given":"Toshimi","family":"Hoshiko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-1362","authenticated-orcid":false,"given":"Yasushi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Akisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"1","key":"862_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K (2014) Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 19(1):3\u20139. https:\/\/doi.org\/10.1007\/s10147-013-0641-7","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"862_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M (2019) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33(5):1173\u20131183. https:\/\/doi.org\/10.1038\/s41375-018-0341-4","journal-title":"Leukemia"},{"issue":"5","key":"862_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561\u2013566","journal-title":"Nat Med"},{"key":"862_CR4","doi-asserted-by":"publisher","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, I. Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med 348(11):994-1004. https:\/\/doi.org\/10.1056\/NEJMoa022457","DOI":"10.1056\/NEJMoa022457"},{"issue":"2","key":"862_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","volume":"54","author":"RS Geary","year":"2015","unstructured":"Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54(2):133\u2013146. https:\/\/doi.org\/10.1007\/s40262-014-0224-4","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"862_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM, Eteplirsen Study Group (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"issue":"10","key":"862_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86(10):890\u2013897. https:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"issue":"1","key":"862_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant\u00e9-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Concei\u00e7\u00e3o I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, BW ME, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary Transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"issue":"1","key":"862_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plant\u00e9-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary Transthyretin amyloidosis. N Engl J Med 379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"862_CR10","doi-asserted-by":"publisher","first-page":"7969","DOI":"10.1038\/ncomms8969","volume":"6","author":"K Nishina","year":"2015","unstructured":"Nishina K, Piao W, Yoshida-Tanaka K, Sujino Y, Nishina T, Yamamoto T, Nitta K, Yoshioka K, Kuwahara H, Yasuhara H, Baba T, Ono F, Miyata K, Miyake K, Seth PP, Low A, Yoshida M, Bennett CF, Kataoka K, Mizusawa H, Obika S, Yokota T (2015) DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun 6:7969. https:\/\/doi.org\/10.1038\/ncomms8969","journal-title":"Nat Commun"},{"issue":"5","key":"862_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5582\/ddt.2016.01065","volume":"10","author":"Y Asami","year":"2016","unstructured":"Asami Y, Yoshioka K, Nishina K, Nagata T, Yokota T (2016) Drug delivery system of therapeutic oligonucleotides. Drug Discov Ther 10(5):256\u2013262. https:\/\/doi.org\/10.5582\/ddt.2016.01065","journal-title":"Drug Discov Ther"},{"issue":"5","key":"862_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1600-0609.2007.00835.x","volume":"78","author":"T Ito","year":"2007","unstructured":"Ito T, Tanaka H, Kimura A (2007) Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 78(5):417\u2013431. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00835.x","journal-title":"Eur J Haematol"},{"issue":"3","key":"862_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2141.2005.05468.x","volume":"129","author":"JM Withey","year":"2005","unstructured":"Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY (2005) Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 129(3):377\u2013380. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05468.x","journal-title":"Br J Haematol"},{"issue":"3","key":"862_CR14","first-page":"252","volume":"86","author":"M Amabile","year":"2001","unstructured":"Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G (2001) Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 86(3):252\u2013259","journal-title":"Haematologica"},{"issue":"2","key":"862_CR15","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1038\/bcj.2017.8","volume":"7","author":"Y Nishida","year":"2017","unstructured":"Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K (2017) The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J 7(2):e527. https:\/\/doi.org\/10.1038\/bcj.2017.8","journal-title":"Blood Cancer J"},{"issue":"11","key":"862_CR16","doi-asserted-by":"publisher","first-page":"e0141946","DOI":"10.1371\/journal.pone.0141946","volume":"10","author":"M Yokoo","year":"2015","unstructured":"Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S (2015) 2-Hydroxypropyl-beta-Cyclodextrin acts as a novel anticancer agent. PLoS One 10(11):e0141946. https:\/\/doi.org\/10.1371\/journal.pone.0141946","journal-title":"PLoS One"},{"issue":"9","key":"862_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s002770000181","volume":"79","author":"KU Chow","year":"2000","unstructured":"Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Boehrer S, Rummel MJ, Stein J, Hoelzer D, Mitrou PS (2000) Induction of apoptosis using 2\u2032,2\u2032 difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 79(9):485\u2013492","journal-title":"Ann Hematol"},{"issue":"1","key":"862_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02983531","volume":"79","author":"S Kimura","year":"2004","unstructured":"Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T (2004) Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 79(1):37\u201343","journal-title":"Int J Hematol"},{"issue":"2","key":"862_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2010.02.008","volume":"294","author":"E Kawata","year":"2010","unstructured":"Kawata E, Ashihara E, Nakagawa Y, Kiuchi T, Ogura M, Yao H, Sakai K, Tanaka R, Nagao R, Yokota A, Takeuchi M, Kimura S, Hirai H, Maekawa T (2010) A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett 294(2):245\u2013253. https:\/\/doi.org\/10.1016\/j.canlet.2010.02.008","journal-title":"Cancer Lett"},{"issue":"4","key":"862_CR20","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101(4):1566\u20131569. https:\/\/doi.org\/10.1182\/blood-2002-06-1685","journal-title":"Blood"},{"issue":"2","key":"862_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-007-0125-z","volume":"7","author":"M Koldehoff","year":"2007","unstructured":"Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7(2):47\u201355. https:\/\/doi.org\/10.1007\/s10238-007-0125-z","journal-title":"Clin Exp Med"},{"issue":"9","key":"862_CR22","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1182\/blood.V91.9.3156","volume":"91","author":"P de Fabritiis","year":"1998","unstructured":"de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F (1998) BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91(9):3156\u20133162","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00862-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00862-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00862-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:40:48Z","timestamp":1678509648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00862-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00862-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. Kimura reports grants from Rena Therapeutics Inc., during the conduct of the study. The remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}